1-7 of 7
Ryohei Katayama
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting Podoplanin for the Treatment of Osteosarcoma

Open Access
Ai Takemoto, Satoshi Takagi, Takao Ukaji, Nobuhiko Gyobu, Mamoru Kakino, Miho Takami, Asami Kobayashi, Marie Lebel, Tokuichi Kawaguchi, Minoru Sugawara, Kazue Tsuji-Takayama, Kenji Ichihara, Yuki Funauchi, Keisuke Ae, Seiichi Matsumoto, Yoshiya Sugiura, Kengo Takeuchi, Tetsuo Noda, Ryohei Katayama, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2633–2645.
https://doi.org/10.1158/1078-0432.CCR-21-4509
Published: 13 June 2022
View articletitled, Targeting Podoplanin for the Treatment of Osteosarcoma
Open the PDF for Targeting Podoplanin for the Treatment of Osteosarcoma in another window
Includes: Supplementary data
Journal Articles

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

Free
Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A. Jänne, Sai-Hong Ignatius Ou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4785–4794.
https://doi.org/10.1158/1078-0432.CCR-20-1630
Published: 15 September 2020
View articletitled, U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention

Free
Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nisiyama, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B02.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B02
Published: 01 September 2018
View articletitled, Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention
Journal Articles

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

Free
Ryohei Katayama, Christine M. Lovly, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2227–2235.
https://doi.org/10.1158/1078-0432.CCR-14-2791
Published: 14 May 2015
View articletitled, Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Open the PDF for Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine in another window
Journal Articles

Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer

Free
Ryohei Katayama, Yuka Kobayashi, Luc Friboulet, Elizabeth L. Lockerman, Sumie Koike, Alice T. Shaw, Jeffrey A. Engelman, Naoya Fujita
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 166–174.
https://doi.org/10.1158/1078-0432.CCR-14-1385
Published: 05 January 2015
View articletitled, Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer
Open the PDF for Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive Cancer in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Free
Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View articletitled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Free
Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4273–4281.
https://doi.org/10.1158/1078-0432.CCR-13-0318
Published: 31 July 2013
View articletitled, ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Open the PDF for ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer in another window